<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01792323</url>
  </required_header>
  <id_info>
    <org_study_id>CIPHER-Clamp</org_study_id>
    <nct_id>NCT01792323</nct_id>
  </id_info>
  <brief_title>Absorption of Insulin Following Subcutaneous Bolus Administration With Different Bolus Durations</brief_title>
  <official_title>Subcutaneous Insulin Absorption Following Bolus Administrations With an Insulin Pump - Comparison of Bolus Administrations With Different Bolus Durations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To cover meal-related insulin requirements, insulin pumps allow insulin to be delivered at&#xD;
      high rates over a short period of time (bolus delivery). The length of this period (bolus&#xD;
      duration) usually depends on the chosen bolus size and on the used insulin pump model. This&#xD;
      study will evaluate the impact of different bolus durations (i.e., durations commonly&#xD;
      employed in commercially available insulin pumps: 2 and 40 seconds for delivering 1 Unit of&#xD;
      insulin) on the pharmacokinetic and pharmacodynamic properties of an rapid-acting insulin&#xD;
      analogue.&#xD;
&#xD;
      Objective: To evaluate in type 1 diabetic patients the pharmacodynamics and pharmacokinetics&#xD;
      of rapid-acting insulin (insulin lispro) administered as subcutaneous boluses with different&#xD;
      bolus durations.&#xD;
&#xD;
      Study design: Single-center, randomized, controlled, two-arm cross-over intervention study&#xD;
&#xD;
      Population: Twenty type 1 diabetic subjects&#xD;
&#xD;
      Intervention: The investigational treatment is the subcutaneous administration of insulin&#xD;
      lispro either as one bolus of 15 IU over a period of 30s or as one bolus of 15 IU over a&#xD;
      period of 10 min. Plasma samples to assess pharmacodynamic and pharmacokinetic properties&#xD;
      will be taken during an 8-hour clamp experiment. Patients will undergo both investigational&#xD;
      treatments in a randomized order; between the two clamp visits there will be a wash-out&#xD;
      period of 5-21 days.&#xD;
&#xD;
      Main study endpoint: Time to maximum glucose infusion rate&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>tmax(GIR); time to maximum glucose infusion rate</measure>
    <time_frame>8 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>GIRmax, maximum glucose infusion rate</measure>
    <time_frame>8 hours</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>tmax(ins), time to maximum observed plasma insulin lispro concentration</measure>
    <time_frame>8 hours</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>1 bolus of insulin lispro with short bolus duration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous administration of insulin lispro as a bolus of 15 IU over a period of 30 seconds</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1 bolus of insulin lispro with long bolus duration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous administration of insulin lispro as a bolus of 15 IU over a period of 10 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin LISPRO</intervention_name>
    <description>Administration of 15 IU of insulin lispro over a period of 30 seconds</description>
    <arm_group_label>1 bolus of insulin lispro with long bolus duration</arm_group_label>
    <arm_group_label>1 bolus of insulin lispro with short bolus duration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent obtained after being advised of the nature of the study&#xD;
&#xD;
          -  Male or female aged 18-60 years (both inclusive)&#xD;
&#xD;
          -  Type 1 diabetes treated with multiple daily insulin injection or continuous&#xD;
             subcutaneous insulin infusion for 12 months&#xD;
&#xD;
          -  Fasting C-peptide &lt; 0.3nmol/L&#xD;
&#xD;
          -  Body mass index 20.0-30.0 kg/mÂ² (both inclusive)&#xD;
&#xD;
          -  HbA1c &lt; 10%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female of childbearing potential who is pregnant, breast-feeding or intend to become&#xD;
             pregnant or is not using adequate contraceptive methods&#xD;
&#xD;
          -  Skin pathology or condition prohibiting needle insertion/insulin administration as&#xD;
             judged by the investigator&#xD;
&#xD;
          -  History of bleeding disorder&#xD;
&#xD;
          -  Current participation in another clinical study&#xD;
&#xD;
          -  Use of insulin lispro &gt;2 weeks&#xD;
&#xD;
          -  Significant acute or chronic illness that might interfere with subject safety or&#xD;
             integrity of results as judged by the investigator&#xD;
&#xD;
          -  Smoker (defined as &gt;5 cigarettes/d)&#xD;
&#xD;
          -  Lipodystrophy&#xD;
&#xD;
          -  Current treatment with systemic (oral or i.v.) corticosteroids, monoamine oxidase&#xD;
             (MAO) inhibitors, non-selective beta-blockers, growth hormone, herbal products or&#xD;
             non-routine vitamins. Furthermore, thyroid hormones are not allowed unless the use of&#xD;
             these has been stable during the past 3 months&#xD;
&#xD;
          -  Significant history of alcoholism or drug abuse or a positive result in urine&#xD;
             drug/alcohol screen&#xD;
&#xD;
        Study Day Exclusion Criteria:&#xD;
&#xD;
          -  Strenuous exercise within the last 24 hours prior to the clamp visit&#xD;
&#xD;
          -  Non-fasting (i.e. consumption of food or beverages, other than water, later than 22:00&#xD;
             hours the evening before the visit) except if slight intake of rapidly absorbable&#xD;
             carbohydrates has been necessary in order to prevent hypoglycaemia&#xD;
&#xD;
          -  Injection of long-acting insulin (e.g. insulin glargine or insulin detemir) later than&#xD;
             12:00 hours (noon), 2 days before the clamp visit&#xD;
&#xD;
          -  Injection of NPH insulin or other intermediate-acting insulin products later than&#xD;
             12:00 hours (noon) on the day before the clamp visit&#xD;
&#xD;
          -  Injection of any short acting insulin (aspart, lispro, glulisine) or more than 6 IU of&#xD;
             human insulin between 22:00 hours and 03:00 hours the night before the clamp visit&#xD;
&#xD;
          -  Injection of any insulin later than 03:00 hours the night before the clamp visit&#xD;
&#xD;
          -  Infusion of any insulin later than 03:00 hours the night before the clamp visit for&#xD;
             subjects using continuous subcutaneous insulin infusion (CSII)&#xD;
&#xD;
          -  Positive result of alcohol breath test&#xD;
&#xD;
          -  Any medical condition that, in the opinion of the Investigator, could interfere with&#xD;
             insulin pharmacokinetics and/or glucose metabolism&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas R Pieber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz, Internal Medicine, Endocrinology and Metabolism</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <state>Styria</state>
        <zip>A-8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <link>
    <url>http://www.medunigraz.at</url>
    <description>Medical University of Graz</description>
  </link>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>February 13, 2013</study_first_submitted>
  <study_first_submitted_qc>February 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2013</study_first_posted>
  <last_update_submitted>February 25, 2014</last_update_submitted>
  <last_update_submitted_qc>February 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Graz</investigator_affiliation>
    <investigator_full_name>Pieber Thomas, MD</investigator_full_name>
    <investigator_title>MD, Prof. of Medicine</investigator_title>
  </responsible_party>
  <keyword>insulin pump therapy</keyword>
  <keyword>insulin bolus</keyword>
  <keyword>rapid acting insulin</keyword>
  <keyword>insulin lispro</keyword>
  <keyword>pharmacodynamics</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>glucose clamp</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

